Page 2 - Tarsu Form News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept Tick-Kill Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease -February 22, 2024 at 08:03 am EST

TP-05 demonstrated tolerability and statistically significant tick mortality, suggesting potential for on-demand Lyme disease prophylaxisIRVINE, Calif., Feb. 22, 2024 Tarsus Pharmaceuticals,.

United statesAdrienne kempDavid nakasoneCenters for diseaseExchange commissionCorporate communicationsTarsus pharmaceuticals incDisease controlTarsus pharmaceuticalsMeibomian gland diseaseTarsu formLyme disease

Now Available – XDEMVY™ (lotilaner ophthalmic solution) 0 25%, the First and Only FDA Approved Treatment for Demodex Blepharitis

Now Available – XDEMVY™ (lotilaner ophthalmic solution) 0 25%, the First and Only FDA Approved Treatment for Demodex Blepharitis
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

United statesAdrienne kempBobak azamianDavid nakasoneExchange commissionCorporate communicationsDrug administrationTarsus pharmaceuticals incTarsus pharmaceuticalsChief executive officerTarsus connectFull prescribing informationMeibomian gland diseaseImportant safety informationSeek physician adviceContact lenses

Tarsus Announces Pricing of $100 0 Million Underwritten Public Offering of Common Stock

IRVINE, Calif., Aug. 01, 2023 Tarsus Pharmaceuticals, Inc. , whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients,.

North carolinaUnited statesNew yorkAdrienne kempDavid nakasoneEquity syndicate departmentCompany or tarsusGuggenheim securitiesSyndicate prospectus departmentProspectus departmentOppenheimer coExchange commissionGoldman sachs coTarsus pharmaceuticals incCorporate communicationsBofa securities

Tarsus Announces Pricing of $100 0 Million Underwritten Public Offering of Common Stock - Tarsus Pharmaceuticals (NASDAQ:TARS)

IRVINE, Calif., Aug. 01, 2023 (GLOBE NEWSWIRE) Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) (the "Company" or "Tarsus"), whose mission is to focus on unmet needs and apply proven science and new technology to

New yorkUnited statesNorth carolinaAdrienne kempDavid nakasoneExchange commissionCorporate communicationsCompany or tarsusProspectus departmentEquity syndicate departmentOppenheimer coTarsus pharmaceuticals incGuggenheim securitiesGoldman sachs coSyndicate prospectus departmentBofa securities

Tarsus Announces Proposed $100 0 Million Underwritten Public Offering of Shares of its Common Stock

Tarsus Announces Proposed $100 0 Million Underwritten Public Offering of Shares of its Common Stock
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

North carolinaUnited statesNew yorkAdrienne kempDavid nakasoneProspectus departmentTarsus pharmaceuticals incExchange commissionCompany or tarsusGuggenheim securitiesCorporate communicationsEquity syndicate departmentOppenheimer coSyndicate prospectus departmentGoldman sachs coTarsus pharmaceuticals